Corbus Pharmaceuticals price target lowered to $40 from $50 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Corbus Pharmaceuticals (CRBP) to $40 from $50 and keeps a Buy rating on the shares. The firm lowered its valuation multiples and increased the stock’s discount rates to better align with current investor sentiment, elevated cost of capital, and reduced appetite for early-stage clinical risk. IT still expects CRB-701’s solid tumor footprint to grow driven by a “best-in-class profile.”